

Deutsche Bank Health Care Conference

May 5, 2010

Shire plc

Angus Russell
Chief Executive Officer



Our purpose

We enable people with life-altering conditions to lead better lives

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire’s products; Shire’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire’s products; Shire’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission.

Shire's business model has been the key to our success

Business Model

- Specialty biopharmaceutical company
- Treatment of symptomatic diseases
- Small sales forces
- Focus on lower risk projects with relatively fast development timelines and strong IP protection


Financial impact past 7 years (2003 – 2009)



	% Growth	CAGR
Revenues	190%	16%
EBITDA	169%	15%

Note: data covers timeframe of 1/1/2003 through 12/31/2009

Q1 2010 Core products replenishing the XR gap



Specialty Pharma – Product highlights

- VYVANSE
 - 14.3%* share of US ADHD market
 - Revenue up 32% versus Q1 2009
 - Clinical trial enrollment progressing well for new indications
- INTUNIV
 - 1.8%* share of US ADHD market
 - 4.3% share among child/adolescent psychiatrists
 - Most commercial managed care plans providing unrestricted access; Medicaid reimbursement progressing as expected
 - Co-administration trial data to be presented at SOBP** meeting in May
- LIALDA
 - 19%* share of US oral mesalamine market
 - Enrollment completed in the ongoing Ph 3 clinical trials for diverticulitis
 - Data anticipated in 2012


* Source: IMS NPA Weekly as of April 23

** The Society of Biological Psychiatry


HGT - Product highlights

- ELAPRASE
 - Revenue up 22% versus Q1 2009
- VPRIV
 - Approaching 500 patients treated with VPRIV globally
 - Approved and launched in the US
 - 13% share of US ERT Gaucher market on VPRIV
 - 80% of patients on the VPRIV t-IND have initiated commercial access
 - Approximately 25% who have initiated commercial access are new to VPRIV
- FIRAZYR
 - Now launched in 13 countries, including the 5 largest European countries
- REPLAGAL
 - Revenue up 69% versus Q1 2009
 - Market leader in EU with estimated 60% market share

190 patients added to REPLAGAL therapy in Q1 2010 with the majority coming from patient switches



2010 Key events



H2-2010

- VYVANSE data from Ph2 non-ADHD trials
- Additional Carrierwave program data available
- SPD 535 (anagrelide analogue) PoC data
- VPRIV EU approval expected
- REPLAGAL US rolling BLA submission targeted
- Manufacturing initiated in new large scale facility in MA

Solid foundation for future growth

- Delivering excellent Q1 results
 - Core product sales* up 36%
 - Strong cash generation and operating margins
- Replenished our product portfolio
 - Driving growth from balanced portfolio of 8 global products
 - Developing, advancing and enhancing our strong pipeline
- Increasing our global reach
 - Direct business in 28 countries and growing
- Aspiration to grow sales in the mid-teens range on average between 2009 and 2015

Questions and Answers



Our purpose

We enable people with life-altering conditions to lead better lives